Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin R Farlow

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
Journal of Lipid Research|February 18, 2005
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's diseaseRoger M Lane, Martin R Farlow
BMC Geriatrics|January 22, 2005
Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 yearsMartin R Farlow, Mary L Lilly,
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 24, 2017
Benefits and harms of atypical antipsychotics for agitation in adults with dementiaMartin R Farlow, Tatyana A Shamliyan
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet|May 20, 2011
RAPID progression: tool for screening aggressive course of disease (ACD) in Alzheimer dementiaNuntika Thavichachart, Puangsoy Worakul, Martin R Farlow
Dementia and Geriatric Cognitive Disorders|April 9, 2008
Treatment options in Alzheimer's disease: maximizing benefit, managing expectationsMartin R Farlow, Michael L Miller, Vojislav Pejovic
Drug Safety|June 19, 2008
Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trialsMartin R Farlow, Stephen M Graham, Gustavo Alva
Current Alzheimer Research|December 20, 2011
Reviewing the role of donepezil in the treatment of Alzheimer's diseaseRachelle S Doody, Jeffrey L Cummings, Martin R Farlow
Neurology and Therapy|July 11, 2018
A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and TreatmentSamuel D Capouch, Martin R Farlow, Jared R Brosch
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 1, 2017
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's DiseaseThomas N Chase, Martin R Farlow, Kathleen Clarence-Smith
Current Medical Research and Opinion|November 26, 2009
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysisMartin R Farlow, Gus Alva, Xiangyi Meng, et al.
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
Journal of Lipid Research|February 18, 2005
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's diseaseRoger M Lane, Martin R Farlow
BMC Geriatrics|January 22, 2005
Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 yearsMartin R Farlow, Mary L Lilly,
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 24, 2017
Benefits and harms of atypical antipsychotics for agitation in adults with dementiaMartin R Farlow, Tatyana A Shamliyan
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet|May 20, 2011
RAPID progression: tool for screening aggressive course of disease (ACD) in Alzheimer dementiaNuntika Thavichachart, Puangsoy Worakul, Martin R Farlow
Dementia and Geriatric Cognitive Disorders|April 9, 2008
Treatment options in Alzheimer's disease: maximizing benefit, managing expectationsMartin R Farlow, Michael L Miller, Vojislav Pejovic
Drug Safety|June 19, 2008
Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trialsMartin R Farlow, Stephen M Graham, Gustavo Alva
Current Alzheimer Research|December 20, 2011
Reviewing the role of donepezil in the treatment of Alzheimer's diseaseRachelle S Doody, Jeffrey L Cummings, Martin R Farlow
Neurology and Therapy|July 11, 2018
A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and TreatmentSamuel D Capouch, Martin R Farlow, Jared R Brosch
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 1, 2017
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's DiseaseThomas N Chase, Martin R Farlow, Kathleen Clarence-Smith
Current Medical Research and Opinion|November 26, 2009
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysisMartin R Farlow, Gus Alva, Xiangyi Meng, et al.
Pageof 19